Analysis of the therapeutic effect of Datopotamab in non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for the majority of lung cancer patients. For patients with advanced or metastatic NSCLC, especially those whose disease has progressed after EGFR-targeted therapy and platinum-based chemotherapy, treatment options are limited and the prognosis is poor. Traditional chemotherapy has limited effects and severe side effects, and there is an urgent need for new treatment options that are more effective and better tolerated. Datopotomab Deruxtecan (Datopotamab Deruxtecan), as an antibody drug conjugate targeting TROP-2, brings new treatment hope to this field.

DatopotamabBy specifically binding to the TROP-2 protein that is highly expressed on the surface of lung cancer cells, the cytotoxic drug conjugate is directly delivered to the interior of the tumor cells and releases potent cytotoxic agents to kill cancer cells. This precise targeting effect not only improves the anti-tumor activity of the drug, but also reduces damage to normal tissue and improves patient tolerance. This mechanism allows Datopotamab to exhibit significant efficacy in patients who have failed traditional treatments.

Based on key clinical trials such as TROPION-Lung01 and TROPION-Lung05, Datopotamab was evaluated after previously receiving EGFR targeted drugs and platinum-based chemotherapy. showed an overall response rate (ORR) of approximately 4 in patients with advanced NSCLC 0%-45%, and the median progression-free survival (PFS) exceeds 6 months. Some patients achieve lasting remission and improve their quality of life. These data demonstrate that Datopotamab provides a new and effective treatment option for patients with refractory NSCLC.

As more clinical trials are conducted, Datopotamab is expected to further establish its position in the treatment of NSCLC. Research is exploring its combination with immune checkpoint inhibitors and other targeted drugs in the hope of maximizing efficacy. In addition, the drug's potential in patients with early-stage NSCLC and different molecular subtypes is also being evaluated. Overall,Datopotamab represents NSCLC a new direction in precision treatment, opening up more treatment possibilities.

Reference materials:https://www.fda.gov/drugs/